What Made H.C. Wainwright Upgrade United Therapeutics’ Stock?


United Therapeutics (UTHR) received a Buy rating and a $195.00 price target from H.C. Wainwright analyst Andrew Fein today. The company’s shares closed last Friday at $163.82, close to its 52-week high of $176.31.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 19.0% and a 54.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Deciphera Pharmaceuticals, and Global Blood Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for United Therapeutics with a $208.17 average price target, a 26.0% upside from current levels. In a report issued on January 19, Oppenheimer also maintained a Buy rating on the stock with a $200.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $176.31 and a one-year low of $75.58. Currently, United Therapeutics has an average volume of 359.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts